Sugi Predict

Sugi Predict / Compounds / SCHEMBL257010

SCHEMBL257010

SCHEMBL257010

Nc1nc(Cl)nc(N)c1[N+](=O)[O-]

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.38
▸ TSHR P16473 2/20 0.38
▸ MAPT P10636 5/20 0.38
▸ SMN1; SMN2 Q16637 3/20 0.38
▸ LMNA P02545 3/20 0.38
▸ NPC1 O15118 3/20 0.38
▸ RAB9A P51151 3/20 0.38
▸ HTT P42858 2/20 0.38
▸ TP53 P04637 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ XBP1 P17861 1/20 0.38
▸ TLR9 Q9NR96 1/20 0.38
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ MGMT P16455 2/20 0.36
▸ PKM P14618 2/20 0.35
▸ CCNA2 P20248 1/20 0.35
▸ CDK2 P24941 1/20 0.35
▸ CCNA1 P78396 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29978776 0.89 MAPT (0.35) ALDH1A1TSHRMAPTSMN1; SMN2LMNA
SCHEMBL2459982 0.89 MAPT (0.35) ALDH1A1TSHRMAPTSMN1; SMN2LMNA
SCHEMBL166184 0.86 MAPT (0.48) ALDH1A1MAPTSMN1; SMN2LMNANPC1
SCHEMBL16096000 0.81 ALDH1A1 (0.33) ALDH1A1TSHRMAPTSMN1; SMN2LMNA
SCHEMBL9640554 0.80 MGMT (0.49) ALDH1A1MAPTSMN1; SMN2LMNANPC1
SCHEMBL27861816 0.80 CCNA2 (0.37) ALDH1A1MAPTSMN1; SMN2LMNANPC1
SCHEMBL3955746 0.77 MGMT (0.44) ALDH1A1TSHRMAPTSMN1; SMN2LMNA
SCHEMBL7014795 0.77 NPSR1 (0.46) ALDH1A1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL27930543 0.76 PKM (0.44) ALDH1A1MAPTSMN1; SMN2LMNANPC1
SCHEMBL31627622 0.76 CCNA2 (0.32) ALDH1A1MAPTNPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120136846-A Pentasix-ring heat-resistant energetic compound, and preparation method and application thereof 西北工业大学 2025-06-13 — — CN claimed
CN-120136846-A Pentasix-ring heat-resistant energetic compound, and preparation method and application thereof 西北工业大学 2025-06-13 — — CN disclosed
US-12064429-B2 Substituted 5-fluoro-1H-pyrazolopyridines and their use ADVERIO PHARMA GMBH (DE) 2024-08-20 — — US disclosed
CN-118271315-A Intermediate for synthesizing vitamin Li Xigu and preparation method and application thereof 上海科胜药物研发有限公司 2024-07-02 — — CN disclosed
US-20220409618-A1 SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE ADVERIO PHARMA GMBH (DE) 2022-12-29 — — US disclosed
US-20220409618-A1 SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE ADVERIO PHARMA GMBH (DE) 2022-12-29 — — US disclosed
US-11439642-B2 Substituted 5-fluoro-1H-pyrazolopyridines and their use ADVERIO PHARMA GMBH (DE) 2022-09-13 — — US disclosed
US-20200397785-A1 SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE ADVERIO PHARMA GMBH (DE) 2020-12-24 — — US disclosed
US-10736896-B2 Substituted 5-fluoro-1H-pyrazolopyridines and their use ADVERIO PHARMA GMBH (DE) 2020-08-11 — — US disclosed
US-10189856-B2 Use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) ADVERIO PHARMA GMBH (DE) 2019-01-29 — — US disclosed
EP-2385942-A1 BENZIMIDAZOLE AND PYRAZOLOPYRIDINE DERIVATIVES FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASES Bayer Pharma Aktiengesellschaft (DE) 2011-11-16 — — EP disclosed
US-20110254572-A1 CAPACITANCE-TYPE SENSOR FUJIKURA LTD. (JP) 2011-10-20 — — US disclosed
WO-2010079120-A1 BENZIMIDAZOLE AND PYRAZOLOPYRIDINE DERIVATIVES FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASES BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-07-15 — — WO disclosed
WO-2010079120-A1 BENZIMIDAZOLE AND PYRAZOLOPYRIDINE DERIVATIVES FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASES BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-07-15 — — WO disclosed
US-20100029653-A1 PYRAZOLOPYRIDINE, INDAZOLE, IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE, PYRAZOLOPYRAZINE AND PYRAZOLOPYRIDINE DERIVATIVES AS STIMULATORS OF GUANYLATE CYCLASE FOR CARDIOVASCULAR DISORDERS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-02-04 — — US disclosed
US-20100029653-A1 PYRAZOLOPYRIDINE, INDAZOLE, IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE, PYRAZOLOPYRAZINE AND PYRAZOLOPYRIDINE DERIVATIVES AS STIMULATORS OF GUANYLATE CYCLASE FOR CARDIOVASCULAR DISORDERS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-02-04 — — US disclosed
US-20100029653-A1 PYRAZOLOPYRIDINE, INDAZOLE, IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE, PYRAZOLOPYRAZINE AND PYRAZOLOPYRIDINE DERIVATIVES AS STIMULATORS OF GUANYLATE CYCLASE FOR CARDIOVASCULAR DISORDERS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-02-04 — — US disclosed
EP-2066666-A1 PYRAZOLOPYRIDINE, INDAZOLE, IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE, PYRAZOLOPYRAZINE AND PYRAZOLOPYRIDINE DERIVATES AS STIMULATORS OF GUANYLATE CYCLASE FOR CARDIOVASCULAR DISORDERS Bayer Schering Pharma Aktiengesellschaft (DE) 2009-06-10 — — EP disclosed
WO-2008031513-A1 PYRAZOLOPYRIDINE, INDAZOLE, IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE, PYRAZOLOPYRAZINE AND PYRAZOLOPYRIDINE DERIVATES AS STIMULATORS OF GUANYLATE CYCLASE FOR CARDIOVASCULAR DISORDERS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-03-20 — — WO disclosed
WO-2008031513-A1 PYRAZOLOPYRIDINE, INDAZOLE, IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE, PYRAZOLOPYRAZINE AND PYRAZOLOPYRIDINE DERIVATES AS STIMULATORS OF GUANYLATE CYCLASE FOR CARDIOVASCULAR DISORDERS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-03-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12064429-B2 Substituted 5-fluoro-1H-pyrazolopyridines and their use PFKP, PON1, FABP3 ALDH1A1 375/4885TSHR 2505/4885MAPT 4407/4885
US-10736896-B2 Substituted 5-fluoro-1H-pyrazolopyridines and their use PFKP, PON1, FABP3 ALDH1A1 375/4885TSHR 2505/4885MAPT 4407/4885
US-11439642-B2 Substituted 5-fluoro-1H-pyrazolopyridines and their use PFKP, PON1, FABP3 ALDH1A1 375/4885TSHR 2505/4885MAPT 4407/4885
US-20200397785-A1 SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE PFKP, PON1, FABP3 ALDH1A1 375/4885TSHR 2505/4885MAPT 4407/4885
US-10189856-B2 Use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) PDE5A, PDE3A, PDE2A ALDH1A1 3504/4885TSHR 3172/4885MAPT 4846/4885
US-20220409618-A1 SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE PFKP, PON1, FABP3 ALDH1A1 375/4885TSHR 2505/4885MAPT 4407/4885
US-20100029653-A1 PYRAZOLOPYRIDINE, INDAZOLE, IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE, PYRAZOLOPYRAZINE AND PYRAZOLOPYRIDINE DERIVATIVES AS STIMULATORS OF GUANYLATE CYCLASE FOR CARDIOVASCULAR DISORDERS PDE3A, PDE2A, PDE3B ALDH1A1 2240/4885TSHR 1972/4885MAPT 4779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.